Justin Walsh
Stock Analyst at Jones Trading
(1.85)
# 1,989
Out of 4,667 analysts
31
Total ratings
16.67%
Success rate
3.65%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $22.19 | +89.27% | 1 | Oct 18, 2024 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $1.22 | - | 2 | Oct 11, 2024 | |
| BLRX BioLineRx | Initiates: Buy | $2 | $0.55 | +266.84% | 1 | Sep 4, 2024 | |
| LNTH Lantheus Holdings | Maintains: Buy | $105 → $146 | $86.45 | +68.88% | 7 | Jul 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $23 | $10.54 | +118.22% | 1 | Jul 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $3.39 | +548.97% | 2 | May 16, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Buy | $16 | $4.07 | +293.12% | 1 | May 10, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $20 | $4.31 | +364.58% | 1 | Apr 17, 2024 | |
| CTSO Cytosorbents | Reinstates: Buy | $4 | $0.92 | +336.73% | 4 | Sep 7, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $20 | $2.99 | +568.90% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.79 | +2,164.72% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $175 | $0.37 | +46,905.10% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $0.21 | +5,096.03% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $1.19 | +6,202.52% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $42.44 | -52.87% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $3.70 | +5,305.41% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.37 | +629.93% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $4.57 | +17,405.47% | 1 | Sep 2, 2021 |
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $22.19
Upside: +89.27%
Theratechnologies
Oct 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.22
Upside: -
BioLineRx
Sep 4, 2024
Initiates: Buy
Price Target: $2
Current: $0.55
Upside: +266.84%
Lantheus Holdings
Jul 25, 2024
Maintains: Buy
Price Target: $105 → $146
Current: $86.45
Upside: +68.88%
Y-mAbs Therapeutics
Jul 11, 2024
Initiates: Buy
Price Target: $23
Current: $10.54
Upside: +118.22%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $3.39
Upside: +548.97%
TriSalus Life Sciences
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.07
Upside: +293.12%
Achieve Life Sciences
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $4.31
Upside: +364.58%
Cytosorbents
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.92
Upside: +336.73%
Prime Medicine
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $2.99
Upside: +568.90%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $0.79
Upside: +2,164.72%
Mar 22, 2023
Initiates: Buy
Price Target: $175
Current: $0.37
Upside: +46,905.10%
Feb 10, 2023
Initiates: Buy
Price Target: $11
Current: $0.21
Upside: +5,096.03%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $1.19
Upside: +6,202.52%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $42.44
Upside: -52.87%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $3.70
Upside: +5,305.41%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $1.37
Upside: +629.93%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $4.57
Upside: +17,405.47%